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Abstract. 
 
Glycosylation has been implicated in the reg-
ulation of CD44-mediated cell binding of hyaluronan 
(HA). However, neither the relative contribution of N- 
and O-linked glycans nor the oligosaccharide structures 
that alter CD44 affinity for HA have been elucidated. 
To determine the effect of selective alteration of CD44 
oligosaccharide composition on the affinity of CD44 for 
HA, we developed a novel strategy based on the use of 
affinity capillary electrophoresis (ACE). Soluble re-
combinant CD44–immunoglobulin fusion proteins 
were overproduced in the mutant CHO cell line ldl-D, 
which has reversible defects in both N- and O-linked 
oligosaccharide synthesis. Using this cell line, a panel of 
recombinant glycosidases, and metabolic glycosidase 
inhibitors, CD44 glycoforms with defined oligosaccha-
ride structures were generated and tested for HA affin-
ity by ACE. Because ldl-D cells express endogenous 
cell surface CD44, the effect of any given glycosylation 
change on the ability of cell surface and soluble CD44 
to bind HA could be compared. Four distinct oligosac-
charide structures were found to effect CD44-mediated 
HA binding: (
 
a
 
) the terminal 
 
a
 
2,3-linked sialic acid on 
N-linked oligosaccharides inhibited binding; (
 
b
 
) the 
first N-linked 
 
N
 
-acetylglucosamine residue enhanced 
binding; (
 
c
 
) O-linked glycans on N-deglycosylated 
CD44 enhanced binding; and (
 
d
 
) 
 
N
 
-acetylgalac-
tosamine incorporation into non–N-linked glycans aug-
mented HA binding by cell surface CD44. The first 
three structures induced up to a 30-fold alteration in 
 
the intrinsic CD44 affinity for HA (
 
K
 
d
 
 
 
5 
 
5 to 
 
.
 
150 
 
m
 
M). The fourth augmented CD44-mediated cellular 
HA avidity without changing the intrinsic HA affinity 
of soluble CD44. 
 
C
 
d
 
44 is currently thought to be the principal cell sur-
face receptor for hyaluronan (HA)
 
1
 
 (Aruffo et al.,
1990; Miyake et al., 1990), a ubiquitous glycosami-
noglycan (GAG) component of extracellular and pericel-
lular matrices (for review see Laurent and Fraser, 1992).
Interaction between cell surface CD44 and HA is pro-
posed to mediate, at least in part, a variety of cellular func-
tions, including cell migration (Thomas et al., 1992), cell–
matrix adhesion (Carter and Wayner, 1988; Aruffo et al.,
1990), cell–cell adhesion (St. John et al., 1990), lymphocyte
activation (Huet et al., 1989; Denning et al., 1990; Galan-
drini et al., 1994; Lesley et al., 1994), and hematopoiesis
(Kincade, 1994; Legras et al., 1997). CD44 is highly poly-
morphic due to alternative splicing of at least 10 exons en-
coding a segment of the membrane proximal extracellular
domain (Screaton et al., 1992, 1993; Tolg et al., 1993) and
variable N- and O-linked glycosylation (Brown et al., 1991;
Jackson et al., 1995). Multiple distinct CD44 isoforms are
generated by incorporation of different combinations of the
variable exons, which provide new oligosaccharide attach-
ment sites resulting in potentially functionally significant
glycosylation changes (Brown et al., 1991; Bennett et al.,
1995
 
a
 
,
 
b
 
; Jackson et al., 1995). The standard and most broadly
expressed isoform, CD44H, contains none of the variable
exons (Stamenkovic et al., 1989). However, CD44H can be
modified by different oligosaccharide structures depend-
ing on the type and activation state of the cell in which it is
expressed (Telen et al., 1986; Jalkanen et al., 1988; Camp
et al., 1991; Jalkanen and Jalkanen, 1992; Hathcock et al.,
1993; Levesque and Haynes, 1996; Takahashi et al., 1996).
The specific glycosyltransferases which regulate CD44 gly-
cosylation and the resulting oligosaccharide structures
have yet to be determined.
Our working hypothesis is that the structural heteroge-
 
Address all correspondence to Ivan Stamenkovic, Department of Pathol-
ogy, Harvard Medical School and Pathology Research, Massachusetts
General Hospital East, 149 13th Street, Charlestown Navy Yard, Boston,
MA 02129. Tel: (617) 726-5634. Fax: (617) 726-5684.
 
1. 
 
Abbreviations used in this paper
 
: ACE, affinity capillary electrophore-
sis; CE, capillary electrophoresis; dMM, deoxymannojirimycin; Endo H,
endoglycosidase H; GAG, glycosaminoglycan; Gal, galactose; GalNAc,
 
N
 
-acetylgalactosamine; GlcNAc, 
 
N
 
-acetylglucosamine; HA, hyaluronan;
HA60, hyaluronan 60-mer; 
 
K
 
d
 
, dissociation constant; KIF, kifunensine;
MO, mesityl oxide; PNGase-F, peptide 
 
N
 
-glycosidase-F; Rg, receptor-
globulin; 
 
R
 
M
 
, relative mobility; wt, wild type.
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neity of CD44 isoforms is responsible not only for deter-
mining the ligand repertoire of CD44, which includes fibro-
nectin (Jalkanen and Jalkanen, 1992), chondroitin sulfate
(Naujokas et al., 1993), osteopontin (Weber et al., 1996),
and at least two heparin-binding growth factors (Bennett
et al., 1995
 
a
 
,
 
b
 
), but also for modulating the HA-binding
ability. Functional diversity among CD44 molecules unre-
lated to variant exon usage is demonstrated by observa-
tions that CD44H or any particular splice-variant can be
active for HA binding when expressed in some cell types
but inactive in others (Stamenkovic et al., 1991; He et al.,
1992; Bartolazzi et al., 1995). In addition, differences in the
ability of a single CD44 isoform to bind HA are apparent
in different activation states of a single cell type. This is
most clearly illustrated in lymphocytes, which bind HA
poorly in the resting state despite expression of CD44H.
Upon activation by cytokines (Murakami et al., 1990;
Hathcock et al., 1993; Katoh et al., 1995), CD3 cross-link-
ing (Galandrini et al., 1994), lipopolysaccharide (Mu-
rakami et al., 1990; Katoh et al., 1995), phorbol esters (Les-
ley et al., 1990; Hyman et al., 1991; Galandrini et al., 1994),
or an in vivo allogeneic immune reaction (Murakami et al.,
1991; Lesley et al., 1994), certain lymphocytes acquire
a CD44-mediated HA-binding property. The observed
change in ability to bind HA requires hours to days and is
associated with a change in glycosylation (Hathcock et al.,
1993), suggesting that CD44 glycosylation may provide
one mechanism for regulating HA affinity. Differences in
CD44 glycosylation may explain both the cell type and cell
activation state dependence of CD44 function.
Differences in HA binding between CD44H and variant
CD44 isoforms expressed in a single cell type have been
attributed to glycosylation. Inclusion of variant exons 8–10,
for example, results in additional O-linked glycosylation,
which reduces HA binding when CD44v8–10 is expressed
in COS cells and in a human melanoma (Bennett et al.,
1995
 
a
 
). Several recent studies have provided evidence that
glycosylation also plays a role in regulating CD44H-medi-
ated cell attachment to surface-bound and soluble HA
(Brown et al., 1991; Hathcock et al., 1993; Katoh et al.,
1995; Lesley et al., 1995; Bartolazzi et al., 1996). In addi-
tion to these cell-based studies, two studies showed that
glycosylation can alter the ability of the purified CD44H
protein to bind HA, indicating that the oligosaccharide
structures on CD44 affect the molecule’s intrinsic affinity
for HA (Lokeshwar et al., 1991; Katoh et al., 1995). Bio-
synthetic studies showed that the HA-binding function
was acquired with N-glycan structures, and in the presence
of tunicamycin, with the O-glycan structures, suggesting a
positive role for both N- and O-linked oligosaccharides.
However, other studies found no effect or an inhibitory
role for O-linked glycosylation (Bennett et al., 1995
 
a
 
;
Lesley et al., 1995). Furthermore, metabolic or enzymatic
N-deglycosylation was found to either augment (Katoh et
al., 1995; Lesley et al., 1995) or abrogate (Sleeman et al.,
1996; Bartolazzi et al., 1996) HA binding. Mutagenesis of
single or multiple N-glycan attachment sites abrogated
HA binding (Bartolazzi et al., 1996), while an inhibitory
role for complex-type N-glycans was suggested by the pos-
itive effects of the metabolic oligosaccharide processing in-
hibitor deoxymannojirimycin (dMM) observed in some, but
not all, cell lines (Lesley et al., 1995; Bartolazzi et al.,
1996). Enzymatic hydrolysis of sialic acid was found to ei-
ther augment or have no effect on HA binding, depending
at least in part on the cell type in which CD44 was ex-
pressed (Katoh et al., 1995; Lesley et al., 1995). Other than
sialic acid, the specific saccharide residues and structural
motifs responsible for these complex effects of glycosyla-
tion have not been characterized. It is also not known
whether the inhibitory effect of sialic acid on the ability of
CD44 to bind HA occurs when the sialic acid is on N- or
O-linked oligosaccharides, nor is it known what impact the
underlying oligosaccharide structure might have. 
The seemingly contradictory results obtained by the dif-
ferent groups may be due to the different cell types and
different experimental approaches used. In addition, inter-
pretation of some of these results is complicated by the
limitations of the approaches used. Reagents that com-
pletely inhibit N-linked glycosylation of all cell surface and
secreted glycoproteins potentially alter the fate of a wide
variety of cellular proteins that may directly or indirectly
affect CD44 function. Mutagenesis of potential N-linked
glycosylation sites, on the other hand, may alter protein
folding, stability, or conformation, which may be critical for
appropriate HA binding. Enzymatic or metabolic deglyco-
sylation of purified glycoprotein can result in protein ag-
gregation that may artifactually alter functional assays. Fur-
thermore, most of the functional assays used have been
qualitative in nature and were not designed to quantita-
tively measure modest differences in ligand affinity, which
may more closely approximate a physiologically relevant
range. Finally, the relative contribution of O- and N-linked
glycosylation remains unresolved, and the identification of
glycoconjugates that alter the ability of CD44 to interact
with HA is lacking.
To overcome the limitations of conventional approaches,
we have adapted affinity capillary electrophoresis (ACE)
to quantitatively assess the effects of glycosylation changes
on CD44 affinity for HA in free solution, and therefore in
the absence of cell surface constraints. Capillary electro-
phoresis (CE) is a molecular analytic method that pro-
vides superior speed, sensitivity, and resolution compared
with conventional electrophoretic and chromatographic
methods. In addition, capillary electrophoresis provides a
rapid and convenient means to assess the affinity of any
protein for its ligand(s) in free solution under near physio-
logical conditions. In several model systems, ACE has re-
cently been shown to provide a method of choice to quan-
titatively determine protein–ligand dissociation constants
in protein–drug, enzyme–inhibitor, and antibody–antigen
interactions (Chu et al., 1992, 1994; Kraak et al., 1992; Go-
mez et al., 1994; Mammen et al., 1995; Gao et al., 1996). In
this work, we describe the first application of ACE to ana-
lyze adhesion receptor–ligand interactions. Comparison of
results from our novel ACE method to more traditional
cell-based flow cytometry and adhesion assays allowed us
to attribute each effect of glycosylation to either (
 
a
 
) an in-
tramolecular mechanism, in which a change in CD44 gly-
cosylation alters the intrinsic affinity of the CD44 extracel-
lular domain, or (
 
b
 
) an intermolecular mechanism, in
which a glycosylation-dependent change in CD44-medi-
ated HA binding requires molecular interactions in a cel-
lular context and therefore is only apparent in cell-based
assays. We have identified four glycoconjugates that have 
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distinct effects on CD44-mediated HA binding, and which
together can provide an explanation for some of the ap-
parently contradictory observations reported in previous
studies.
 
Materials and Methods
 
Flow Cytometry
 
After nearing or reaching confluence (HAM’s F-12, 10% FBS), cell
monolayers were cultured in serum-free media (HAM’s F-12) containing
either no additions or supplemented with 20 
 
m
 
M galactose (Gal) alone,
200 
 
m
 
M 
 
N
 
-acetylgalactosamine (GalNAc) alone, both Gal and GalNAc,
and/or 2 
 
m
 
g/ml Swainsonine or the combination of 90 
 
m
 
g/ml deoxyman-
nojirimycin (dMM; Toronto Research Chemicals Inc., North York, Ontario,
Canada) and 5 
 
m
 
g/ml kifunensine (KIF; Toronto Research Chemicals
Inc.) for 4 d with one culture medium replacement on day 2. EDTA-
detached cells (6 
 
3 
 
10
 
5
 
), preincubated with 2 ml of hybridoma superna-
tant from KM-81 rat anti–mouse CD44 mAb (American Type Culture
Collection, Rockville, MD) or from an isotype-matched unrelated antibody
for 30 min at 4
 
8
 
C, were stained with fluorescein-conjugated high–molecu-
lar weight HA (Anika, Woburn, MA) (2 
 
m
 
g/ml) or FITC-conjugated goat
anti–rat IgG (Cappel, Malvern, PA) in 500 
 
m
 
l wash buffer (DME, 0.15%
polyvinylpyrrolidone, 0.02% sodium azide, supplemented with 1 M sodium
Hepes, pH 7.0, to 15 mM final concentration) for 1 h in the dark at 4
 
8
 
C,
washed twice with ice-cold wash buffer, and resuspended in PBS for
FACS
 
®
 
 analysis. Single cells were gated from doublets, debris, and dam-
aged cells by light scatter.
 
Cell Adhesion
 
96-well microplates (flat well MaxiSorp; Nunc, Roskilde, Denmark) were
coated with 100 
 
m
 
l/well 1 mg/ml high–molecular weight HA (human um-
bilical cord, Sigma, St. Louis, MO) or 1% BSA in PBS overnight at 4
 
8
 
C.
After a 30-min wash with 1% BSA in PBS, plates were blocked with 1%
denatured BSA in PBS for 30 min at room temperature. Ldl-D (American
Type Culture Collection; Krieger et al., 1989) or CHO cells cultured in se-
rum-free HAM’s F-12 with or without 20 
 
m
 
M Gal and/or 200 
 
m
 
M GalNAc
were EDTA-detached, preincubated with KM81 anti-CD44 hybridoma
supernatant or an isotype-matched unrelated antibody, and allowed to ad-
here to the HA- or BSA-coated wells (10
 
5
 
 cells in 100 
 
m
 
l serum-free me-
dia/well) for 30 min at 37
 
8
 
C. Nonadherent cells were removed by three
washes with 1% BSA in PBS under agitation. Adherent cells were quanti-
tated using CellTiter 96 (Promega Corp., Madison, WI) by measuring the
enzymatic conversion of a tetrazolium dye during a 4-h incubation at
37
 
8
 
C. After overnight solubilization, the amount of dye formation was de-
termined by absorbance at 595 nm on a microplate reader. The percent of
adherent cells is calculated by dividing absorbance of the washed wells by
that of identical unwashed wells. The mean of four wells was used for each
reported value.
 
Production of CD44 Receptorglobulins Glycan Variants
 
A cDNA construct encoding a soluble fusion protein composed of the ex-
tracellular domain of CD44H fused to human IgGFc (CD44 receptorglob-
ulin [CD44Rg]; Aruffo et al., 1990) was stably transfected into CHO and
ldl-D cells. Confluent monolayers of the transfected cells were switched to
culture medium lacking serum and supplemented with no sugar, 20 
 
m
 
M
Gal, 200 
 
m
 
M GalNAc, or both Gal and GalNAc with or without 90 
 
m
 
g/ml
dMM/5 
 
m
 
g/ml KIF or 2 
 
m
 
g/ml Swainsonine. After 2 d, the culture medium
was discarded to allow depletion of cellular stores of Gal and/or GalNAc.
Cell monolayers were then cultured for an additional 10 d with one me-
dium replacement (or 5 d for dMM/KIF-containing cultures). CD44Rg from
filtered culture supernatants, adjusted to pH 8.0 with NaOH, was bound
to protein A–Sepharose, rinsed with H
 
2
 
O, eluted with 20 mM H
 
3
 
PO
 
4
 
, neu-
tralized with 100 mM NaOH, quantitated by UV absorbance at 280 nm
(BSA standard), aliquoted, lyophilized, and stored at 
 
2
 
70
 
8
 
C. Aliquots
were resuspended in H
 
2
 
O immediately before glycosidase digestion and/
or capillary electrophoresis analysis. 
 
Affinity Capillary Electrophoresis 
 
Affinity capillary electrophoresis (ACE) was performed on a capillary
electropherograph (model 3850; Isco, Lincoln, NE) using an uncoated sil-
ica capillary (75 
 
m
 
M i.d., 64 cm length, 40.5-cm inlet to detector window,
ISCO), a 5-s vacuum injection (10 nl), 15 kV (95 
 
m
 
A), and 210-nm UV ab-
sorbance detection in 50 mM NaPO
 
4
 
, pH 7.4. Buffer chambers and capil-
lary containing hyaluronan 60-mers (HA60, Anika, Woburn, MA) were
equilibrated at electrophoresis conditions for 13 minutes after each change
in HA60 concentration. Samples (10 
 
m
 
l) contained 1–2 
 
m
 
M CD44Rg and
480 
 
m
 
g/ml mesityl oxide (MO). Mobility (
 
m
 
) of a given molecule is defined
as its anodal migration relative to MO, the neutral marker, and is deter-
mined from migration times by 
 
m
 
 
 
5 
 
l
 
d
 
(
 
l
 
c
 
/
 
V
 
)(1/
 
t
 
eo
 
 2
 
 1/
 
t
 
), where 
 
l
 
d
 
 is the in-
let to detector window length, 
 
l
 
c
 
 is the capillary length, 
 
V
 
 is applied volt-
age, 
 
t
 
eo
 
 is the migration time for MO, 
 
t
 
 is the migration time for the
molecule of interest, and the units for 
 
m
 
 are V
 
2
 
1
 
min
 
2
 
1
 
cm
 
2
 
. Migration
times for HA60 are determined from the inverted peak resulting from the
lack of HA60 in the sample plug. The mobility of CD44Rg in the presence
of ligand is reported as a relative mobility, where a relative mobility of 0.0
is the mobility of CD44Rg in the absence of ligand, and a relative mobility
of 1.0 is given as the mobility of the free ligand (HA60). Therefore, the
relative mobility of CD44Rg at a given concentration of HA60 is given by
relative mobility 
 
5 
 
(
 
m
 
pl
 
 
 
2 
 
m
 
p
 
)/ (
 
m
 
l
 
 
 
2 
 
m
 
p
 
), where 
 
m
 
pl
 
 is the mobility of
CD44Rg in the presence of HA60, 
 
m
 
p
 
 is the mobility of CD44Rg in the ab-
sence of HA60, and 
 
m
 
l 
 
is the mobility of HA60. 
 
m
 
pl
 
 and 
 
m
 
l 
 
are determined
from the migration times of MO, CD44Rg, and HA60 for each ACE run
containing HA60. 
 
m
 
p
 
 is determined from the migration times of MO and
CD44Rg from replicate CE runs performed in the absence of HA60 and is
used to determine the relative mobility for each ACE run performed in
the presence of HA60 on the same day. 
 
Radiolabeling and Immunoprecipitation
 
[
 
35
 
S]methionine labeling of CHO or ldl-D cells was performed and cell ly-
sates were prepared as previously described (Camp et al., 1991). Cell ly-
sates, precleared for 1 h at 4
 
8
 
C with goat anti–rat IgG coupled protein
A–Sepharose CL4B (Zymed Labs, So. San Francisco, CA) in the presence
of nonimmune rat IgG, were immunoprecipitated using goat anti–rat IgG
coupled protein A–Sepharose CL4B in the presence of KM-81 rat anti–
mouse CD44 IgG2a monoclonal antibody. Immunoprecipitates were sub-
jected to SDS–10% PAGE, and the gels were dried and analyzed after
exposure for autoradiography.
 
Glycosidase Digestion
 
Glycosidases were obtained from Glyko (Novato, CA) except endogly-
cosidase F (Endo F; 
 
N
 
-glycosidase F–free, Boehringer Mannheim Corp.,
Indianapolis, IN). 2 
 
m
 
g CD44Rg adjusted to recommended pH with
H
 
3
 
PO
 
4
 
 or NaOH was incubated with 4.8 
 
m
 
g MO and with or without
(mock) 0.3–2 
 
m
 
l of each glycosidase in a final volume of 10 
 
m
 
l at 37
 
8
 
C until
reaction completion as assessed by CD44Rg migration shift and peak
width on CE analysis. Upon completion of the glycosidase reactions, sam-
ples were analyzed for HA affinity by ACE in the presence of HA60. Ag-
gregation of CD44Rg after deglycosylation was assessed by changes in CE
mobility; all ACE experiments were performed using monomer CD44Rg.
Enzyme-only control CE runs lacking CD44Rg were performed to assure
no interference of the CD44Rg peak by glycosidase protein. 
 
Results
 
Selective Rescue of N- and O-linked Glycosylation in
a Cell Line with a Reversible Glycosylation Defect Has 
Distinct Effects on CD44-mediated HA Binding
 
Wild-type (wt) CHO fibroblasts, which constitutively ex-
press CD44H, display heterogeneous soluble fluorescein
(FITC)-labeled HA binding. The ability of the anti-CD44
antibody KM81 to block the binding of soluble HA to in-
tact cells, as assessed by FACS
 
®
 
 analysis, indicates that
HA binding to CHO cells and their ldl-D derivative (see
below) is CD44 mediated. Assessment of the effects of gly-
cosylation changes on the affinity for HA of CD44-bearing
cells was facilitated by the use of a mutant CHO clone, ldl-D,
which lacks 4-epimerase activity (Fig. 1 
 
A
 
). Ldl-D cells are
unable to use glucose from the culture media to generate 
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UDP-Gal and UDP-GalNAc, the high-energy sugar do-
nors for all synthetic Gal and GalNAc transfer reactions.
Therefore, they generate glycoproteins with truncated or
absent oligosaccharide side chains (Krieger et al., 1989).
Reversal of the inability to synthesize N- and O-linked gly-
cans can be achieved by supplementing the ldl-D cell cul-
ture media with the appropriate monosaccharide, i.e., Gal
and GalNAc, respectively (Fig. 1 
 
B
 
). Selective glycosylation
rescue of the mutant ldl-D cells resulted in marked differ-
ences in their ability to bind soluble HA (Fig. 2), while Gal
and/or GalNAc addition to serum-free cultures of wild-
type CHO cells had no effect on their binding of FITC-
labeled HA (data not shown). Restoration of the ability to
synthesize GalNAc-containing glycan structures resulted
in increased HA binding, while selective incorporation of
Gal-inhibited binding. These two effects appeared to be
independent of each other. Supplementation of the cell cul-
ture medium with both Gal and GalNAc, which fully re-
verses the deficiency in oligosaccharide synthesis, resulted
in ldl-D cell binding of HA comparable to that of wild-
type CHO cells. These findings indicate that there are at
least two glycosylation-dependent effects on CD44-medi-
ated HA binding by whole cells: GalNAc-dependent en-
hancement and Gal-dependent inhibition.
Since glycosylation-rescued ldl-D cells display a similar
level of HA-binding heterogeneity as the parental CHO cells,
it appears unlikely that the HA-binding heterogeneity is
the result of genetic diversity among the parental CHO
population. Moreover, altered glycosylation can reduce this
heterogeneity, as shown by the uniform high affinity bind-
ing of HA in the presence of GalNAc supplementation
alone (Fig. 2). Loss of HA-binding heterogeneity is not
due to the absence of Gal per se, since HA-FITC–binding
heterogeneity is observed in the absence of sugar supple-
mentation at low concentrations of HA-FITC.
High levels of CD44 cell surface protein expression by
CHO and ldl-D cells were observed by FACS
 
®
 
 analysis
under each of the glycosylation conditions. Conditions al-
lowing GalNAc incorporation resulted in slightly higher
surface CD44 expression than conditions lacking GalNAc
incorporation. The mean fluorescence intensities for CD44
expression were: CHO wt, 151; ldl-D Gal/GalNAc, 209;
ldl-D GalNAc only, 164; ldl-D Gal only, 125; and ldl-D no
addition, 109. These moderate variations in surface ex-
pression do not account for the marked differences in
CD44-mediated binding of soluble HA.
 
Galactose-dependent Inhibition of HA Binding Is 
Related to the Number of Complex-Type N-linked 
Oligosaccharide Termini While GalNAc-dependent 
Enhancement of Binding Is Attributed to
Non–N-linked Glycans
 
The galactose-dependent inhibitory and the GalNAc-depen-
Figure 1. Generation of CD44 glycovariants. (A) Ldl-D cells lack
4-epimerase. The reversible N- and O-linked glycosylation defect
in ldl-D cells is due to the lack of a functional 4-epimerase. Cul-
ture medium supplementation with Gal and/or GalNAc reverse
the N- and O-linked glycosylation defects, respectively. (B) Ldl-D
oligosaccharide structures. GalNAc is required to initiate O-linked
glycosylation, which is absent without GalNAc supplementation.
Gal is required to complete the terminal modifications of com-
plex-type N-linked oligosaccharides and many O-linked oligosac-
charides. Truncated N- and O-linked oligosaccharide structures
are generated in the absence of Gal supplementation. (C) Gly-
cans after mannosidase inhibition and glycosidase treatment.
High mannose–type N-linked oligosaccharides are generated in
the presence of dMM and KIF, metabolic inhibitors of a man-
nosidase I. Hybrid type N-linked oligosaccharides are generated in
the presence of swainsonine, an a mannosidase II inhibitor. The
oligosaccharide structures remaining on CD44Rg after Endo H
digestion of high mannose–type N-linked oligosaccharides or PNG-
ase-F digestion are shown. Skelton et al. Glycosylation-mediated Effects on CD44-Hyaluronan Binding 435
dent enhancing effects on cellular avidity for HA could be
due to N- or O-linked glycosylation of the CD44 glycopro-
tein or glycoconjugates of other cellular proteins that indi-
rectly effect CD44 function. To examine the role of the
N-linked oligosaccharides, we treated CHO cells with three
metabolic mannosidase inhibitors, dMM, KIF, and swain-
sonine, to block N-linked oligosaccharide processing, thus
preventing complex-type oligosaccharide synthesis (Kaushal
and Elbein, 1994) (Fig. 1 C). We found that treatment with
a combination of dMM and KIF, both a-mannosidase I in-
hibitors, converted all cell surface CD44 N-linked glycans
to high-mannose structures, while treatment with dMM
alone only partially blocked N-linked glycoconjugate pro-
cessing to complex-type oligosaccharides. Treatment with
swainsonine, an a-mannosidase II inhibitor, resulted in
cell surface expression of CD44 molecules containing hy-
brid type N-linked oligosaccharides in which only one
branch terminates in sialic acida2-3Galb1-4GlcNAcb1-
(Fig. 1 C). Cells grown in the presence of dMM and KIF
displayed increased HA binding compared with those with
intact complex-type N-glycans (CHO, ldl-D Gal only, and
ldl-D Gal/GalNAc; Fig. 3 A and data not shown). In con-
trast, dMM/KIF treatment had no effect on HA binding by
cells lacking galactose-containing oligosaccharides (ldl-D no
addition, ldl-D GalNAc only; Fig. 3 A and data not shown).
In other words, cells expressing CD44 containing trun-
cated N-linked glycans bound soluble HA as well as cells
expressing CD44 containing high-mannose structures. The
observation that ldl-D cells grown in the presence of Gal
and dMM/KIF or in the absence of Gal display comparable
avidity for HA indicates that the inhibitory effect of galac-
tose can be attributed to its incorporation into N-linked
structures. By contrast, the inability of dMM/KIF treat-
ment to modify the observed GalNAc-dependent gain of
function suggests that this effect may primarily be attrib-
uted to non–N-linked glycans, possibly O-linked structures.
Figure 2. Effect of glycosyla-
tion on the binding of soluble
HA to CHO or ldl-D cells.
HA binding to ldl-D cells
was assessed by FACS® anal-
ysis performed using the in-
dicated concentrations of
FITC-HA, and CHO or ldl-D
cells that were cultured for 4 d
with the indicated saccha-
ride additions. HA binding
was performed after preincu-
bation of cells with blocking
anti-CD44 antibody KM-81
(dotted line) or an isotype-
matched unrelated antibody
(solid line). The same results
were obtained from four
other experiments.The Journal of Cell Biology, Volume 140, 1998 436
Similar to dMM/KIF-treated cells containing high-man-
nose oligosaccharides, hybrid-type oligosaccharide-bear-
ing cells, as a result of swainsonine treatment, displayed
enhanced HA binding compared to cells bearing intact
complex-type structures (CHO, ldl-D Gal only, ldl-D Gal/
GalNAc; Fig. 3 B and data not shown). However, unlike
the effect of dMM/KIF treatment, cells treated with swain-
sonine had a slightly poorer avidity for HA when grown in
the presence than when grown in the absence of Gal (ldl-D
Gal only , ldl-D no addition and ldl-D Gal/GalNAc ,
ldl-D GalNAc only; Fig. 3 B and data not shown). These
observations indicate that hybrid structures containing a
single branch terminating with NeuAc-Gal provide a partial
inhibitory effect, weaker than that of intact complex-type
oligosaccharides containing multiple NeuAc-Gal terminat-
ing branches. As expected, swainsonine had no significant
effect on HA binding by cells grown under conditions that
resulted in expression of truncated complex-type oligosac-
charides (ldl-D no addition, ldl-D GalNAc only; Fig. 3 B
and data not shown). The level of CD44 surface expression
as measured by FACS® analysis was modestly increased in
the presence of GalNAc but unaltered by dMM/KIF or
swainsonine treatment under all glycosylation conditions
(data not shown). 
Selective N- and O-linked Glycosylation
Promotes Differential Adhesion of ldl-D Cells to a 
Hyaluronan-coated Surface
To determine whether these same glycosylation-depen-
dent effects apply to CD44-mediated cell attachment to
HA, we tested the ability of ldl-D cells to adhere to HA-
Figure 3. Effect of mannosi-
dase inhibitors on the bind-
ing of soluble HA to CHO or
ldl-D cells. HA binding to
ldl-D cells was assessed by
FACS® analysis performed
using 2 mg/ml FITC-HA,
and CHO or ldl-D cells that
were cultured for 4 d with the
indicated metabolic inhibitor
and/or saccharide additions.
HA binding was performed
after preincubation of cells
with blocking anti-CD44 an-
tibody KM-81 (dotted line) or
an isotype-matched unre-
lated antibody (solid line). A
and B were from separate ex-
periments.  The results from
A were repeated in two other
experiments and from B in
one other experiment with
similar results.Skelton et al. Glycosylation-mediated Effects on CD44-Hyaluronan Binding 437
coated plastic after selective or complete glycosylation re-
constitution (Fig. 4). Similar to binding of soluble HA,
we observed GalNAc-dependent augmentation and Gal-
dependent reduction of ldl-D cell attachment to surface-
bound HA. Cell adhesion to substrate coated with HA
could be completely blocked by the anti-CD44 antibody
KM-81 but not by unrelated antibodies, confirming that
it was CD44 mediated. Treatment of the cells with dMM/
KIF resulted in increased adhesion under conditions of ga-
lactose incorporation (CHO, ldl-D Gal/GalNAc, and ldl-D
Gal only) but had no significant effect on adhesion under
conditions lacking galactose incorporation (ldl-D no addi-
tion, ldl-D GalNAc only, data not shown). These observa-
tions are consistent with inhibition of CD44-mediated cell
attachment to HA by galactose-containing termini of com-
plex-type N-linked oligosaccharides and enhancement of
adhesion by GalNAc-containing non–N-linked glycans
and are similar to those on the effects of the same glycosy-
lation changes on soluble HA binding. It must be noted,
however, that cell attachment and soluble HA-binding as-
says may preferentially measure different aspects of CD44
function. Nonetheless, our results suggest that glycosyla-
tion regulates these CD44 functions by similar mechanisms.
Differences in Glycosylation Do Not Cause 
Redistribution of Cell Surface CD44
The glycosylation-dependent alterations of the ability of
cell surface CD44 to bind HA could be due to changes in
glycosylation of CD44 itself, resulting in an altered intrin-
sic HA affinity of the CD44 glycoprotein or altered CD44
distribution, oligomerization, or interaction with accessory
molecules. To address the possibility of glycosylation-depen-
dent redistribution of the CD44 molecules on the cell sur-
face, cell surface CD44 expression of ldl-D monolayers
cultured in the presence or absence of Gal and/or GalNAc
was assessed by immunofluorescence using the anti-CD44
mAb KM-81. Diffuse CD44 cell surface staining was ob-
served under all four saccharide supplementation condi-
tions showing that the HA-avidity changes were not due to
gross CD44 clustering or capping (data not shown). SDS-
PAGE of endogenous cell surface CD44H immunopre-
cipitated from ldl-D cell lysates displayed glycosylation-
dependent migration shifts, confirming the alteration of
CD44 oligosaccharide structures as a result of selective or
combined saccharide supplementation (Fig. 5). In addition
to monosaccharides, serum can serve as an exogenous
source of Gal and GalNAc via cellular uptake and degra-
dation of serum glycoproteins (Krieger et al., 1989). Under
nonreducing conditions, a small amount of CD44 multi-
mer formation could be observed. However, the amount
of CD44 multimerization apparent on nonreducing SDS-
PAGE was unaltered by glycosylation changes in ldl-D cells
(Fig. 5), rendering unlikely the possibility that changes in
CD44H oligomerization provide a mechanism for the ob-
served alterations in HA binding.
Development of a Novel Strategy to Analyze Soluble 
CD44 Binding to HA 
Ldl-D and wild-type CHO cells were stably transfected
with a cDNA encoding a soluble fusion protein, termed
CD44 receptorglobulin (CD44Rg), composed of the extra-
cellular domain of CD44 and the Fc portion of human
IgG1 (CD44Rg; Aruffo et al., 1990; Thomas et al., 1992).
N- and O-linked glycan variants of CD44Rg were purified
from supernatants of ldl-D and wt CHO cells and their af-
finity for HA assessed by ACE. ACE relates changes in
electrophoretic mobility of a protein upon complexation
Figure 4. Effect of glycosylation on CD44-mediated ldl-D cell
adhesion to HA. CHO or ldl-D cells grown with the indicated
saccharide supplementation for 4 d were seeded onto BSA-
(BSA-Coated) or HA-coated plates after preincubation with
blocking anti-CD44 monoclonal antibody, KM-81 (HA 1 KM81)
or an isotype-matched unrelated antibody (HA-Coated). The per-
centage of adherent cells is reported as the mean of quadrupli-
cate wells with the error bars representing the standard deviation.
The same results were obtained in two other independent experi-
ments.
Figure 5. Effect of glycosylation on SDS-PAGE mobility of en-
dogenous CD44H from ldl-D cells. Immunoprecipitates of CD44
from [35S]methionine-labeled ldl-D cells cultured for 4 d with:
10% FBS (lanes 1 and 6), no supplementation (lanes 2 and 7),
Gal only (lanes 3 and 8), GalNAc only (lanes 4 and 9), or Gal 1
GalNAc (lanes 5 and 10) were analyzed by SDS-PAGE under
nonreducing (lanes 1–5) and reducing (lanes 6–10) conditions.
Molecular mass (kD) is indicated.The Journal of Cell Biology, Volume 140, 1998 438
with ligand present in the buffer to the affinity of the re-
ceptor–ligand pair. The dissociation constant can be calcu-
lated from the magnitude of the change in protein mobility
as a function of ligand concentration. Purified HA 60-mers
were used as the CD44 ligand to avoid potential problems
associated with size heterogeneity of high–molecular weight
HA polymer. Binding of high–molecular weight and 60-
mer HA to CD44 on the cell surface was observed to be
comparable, as assessed by flow cytometry (data not shown). 
Because the dissociation rate for CD44Rg and HA60
was rapid compared with electrophoresis duration (data
not shown), we included HA60 in the capillary and elec-
trophoresis buffer and CD44Rg in the sample only. Bind-
ing of the negatively charged HA60 to CD44Rg in free so-
lution imparts a greater negative charge-to-mass ratio on
CD44Rg, thus delaying its migration, which is driven by
electroosmosis and resisted by electrophoretic attraction
to the anode inlet. During electrophoresis, the interaction
between CD44Rg and HA60 is in rapid equilibrium. Thus,
the shift in migration time of CD44Rg induced by the
presence of ligand is related to the degree to which it is
complexed with HA60. Specifically, during CE the mole-
cules are in free solution and are resolved on the basis of
their charge to mass ratio, where electrophoretic mobility
is proportional to
(1)
where m is electrophoretic mobility, Z is the ionic charge,
M is the mass, and C is a proportionality constant specific
to a given group of molecules (Rickard et al., 1991; Chu et al.,
1992). We found considerable variation in electroosmotic
flow from one experiment to another, which can be cor-
rected for by including an internal neutral marker, MO, in
the sample. Mobilities determined relative to MO yield re-
producible results. The coefficient of variation (CV) for
electroosmotic flow was found to be 8.72%, while the CV
for CD44Rg mobility was 2.16% (data not shown). The
mobility of a given molecule is experimentally determined
from its anodal migration relative to MO by:
(2)
where ld is the length of capillary to the detector window
(40.5 cm), lc is the length of the capillary (64 cm), V is ap-
plied voltage (15,000 V), teo is the migration time for MO,
and t is the migration time for the molecule of interest
(Gomez et al., 1994). Determining the mobility shifts of
CD44Rg as a function of varying concentrations of HA60
in the buffer and capillary allows determination of the af-
finity of the CD44Rg glycan variants for HA. The change
in CD44Rg mobility induced by ligand is reported as a rel-
ative mobility (RM), defined as the mobility of CD44Rg in
the presence of ligand relative to the mobility of CD44Rg
without ligand (RM 5 0) and the mobility of free ligand
(HA60) (RM 5 1). Specifically, the mobility shift is given by
(3)
where mpl is the mobility of CD44Rg in presence of ligand,
mp is the mobility of CD44Rg in the absence of ligand, and
ml is the mobility of HA60. 
HA60 induced a concentration-dependent mobility shift
of wt CHO-derived CD44Rg but failed to change the mo-
m C 2ZM
23 ¤
¤ () , »
m 1 d 1 c V ¤ () 1 t eo ¤ 1 t ¤ – () , =
R M m pl ( mp )/ ml mp – () , – =
bility of the noninteracting protein, BSA (Fig. 6, A and B).
CD44Rg molecules synthesized by ldl-D cells cultured in
the presence of Gal displayed the same relative mobilities
as wt CHO cell–derived CD44Rg, but those synthesized in
the absence of Gal displayed greater relative mobilities
because of a higher affinity for HA at any given concentra-
tion of HA60 (Fig. 6, A and C–F). Dissociation constants
(Kd) were determined by fitting curves to the data using
(4)
where RM is the relative mobility, RM (max) is the maximum
relative mobility (mobility of CD44Rg at saturating con-
centrations of HA60), Kd is the dissociation constant, and
[HA60] is the concentration of HA 60-mer. Affinities de-
termined from Fig. 6 G revealed dissociation constants (Kd)
of 40 and 5 mM for HA60 binding of Gal-bearing and Gal-
lacking CD44Rg glycoproteins, respectively. Thus, incor-
poration of Gal into the oligosaccharides of CD44 results
in an eightfold lower affinity of soluble CD44 for HA60
and provides a plausible explanation for the reduced bind-
ing of soluble HA by ldl-D cells cultured in Gal-supple-
mented medium (Fig. 2). In contrast, the intrinsic affinity
for HA of the CD44 molecule is independent of GalNAc
incorporation into CD44 oligosaccharides, unlike whole
cells where GalNAc supplementation increases CD44-medi-
ated binding of HA. These observations indicate that
GalNAc-dependent enhancement of CD44-mediated HA
binding by cells is governed by a mechanism requiring the
cellular context and is not caused by structure/function
changes limited to the extracellular domain of the CD44
glycoprotein itself. 
N-linked Oligosaccharide Structures Can Both 
Enhance and Reduce CD44 Affinity for HA: Reduction 
of Affinity is Due to a2,3-linked Sialylation 
To further define the specific oligosaccharide structures
involved in the regulation of CD44 affinity for HA, we
analyzed CD44Rg-HA binding by ACE after glycosidase
digestion of the CD44Rg glycan variants. A variety of
CD44Rg glycovariants were found to give RM (max) values
of about 0.54, despite having different CE mobilities in the
absence of ligand (Fig. 6). We could therefore compare
different CD44 glycovariants in an ACE experiment using
a single concentration of HA60 and estimate the Kd from
the saturation equation (Eq. 4) by assuming a RM (max) of
0.54. Sequential trimming of CD44Rg N-linked oligosaccha-
rides with specific glycosidases followed by determination
of relative affinities for HA60 by ACE allowed determina-
tion of the functional contributions for each saccharide resi-
due. Gal is required for the terminal modifications of com-
plex N-linked and many O-linked oligosaccharides, while
GalNAc is required for any O-linked structure (Fig. 1 B).
Since the observed Gal-associated inhibition of HA bind-
ing by CD44Rg is GalNAc independent, Gal-dependent
inhibition must be related to the terminal glycosylation of
CD44 N-linked oligosaccharides. The N-linked oligosac-
charides of CHO cell CD44Rg terminate with NeuAca2,3-
Galb1,4-GlcNAcb- (Skelton, T.P., and I. Stamenkovic, un-
published). Removal of sialic acid with an a2,3-specific
neuraminidase (N1) was sufficient to convert GalNAc 1
Gal–supplemented ldl-D cell–derived CD44Rg from a
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moderate to a high-affinity binder of HA (Fig. 7), and ad-
ditional glycosidase trimming of the terminal residues had
no further enhancing effect. The mean dissociation con-
stants from several such experiments are shown in Table I.
For simplicity, relative mobilities corresponding to Kd val-
ues of 5–19, 20–79, and 80–319 mM will hitherto be re-
ferred to as high-, intermediate-, and low-affinity binding,
respectively. These observations demonstrate that the in-
hibitory effect of galactose incorporation is due to the abil-
ity of galactose to accept terminal sialic acid residues and
not to the galactose residue per se. To confirm that termi-
nal N-linked glycan modifications are responsible for the
decreased CD44 affinity for HA, we performed the same
functional analysis, after stepwise glycosidase removal of
the oligosaccharide termini, on CD44Rg lacking O-linked
oligosaccharides and observed comparable changes in HA
binding affinity (ldl-D Gal only; Fig. 7 F). Inhibition of
HA binding associated with sialylation is therefore due to
N-linked but not to O-linked sialic acid.
To determine whether the remaining core N-linked
structure has an effect on HA affinity, the entire N-linked
oligosaccharide was enzymatically removed by peptide N-gly-
cosidase F (PNGase-F) before ACE analysis (Fig. 1 C).
PNGase-F treatment of Gal/GalNAc-reconstituted ldl-
D–derived CD44Rg resulted in moderate HA affinity,
similar to or slightly lower than that of the untreated mole-
cule (Fig. 7 E, Table I). Thus, in addition to removing the
inhibitory effect of the terminal sialic acid, a positive effect
of the N-glycan was also abrogated. Successful enzymatic
hydrolysis was confirmed by a small shift in CD44Rg CE
mobility (in the absence of ligand), as well as a marked
loss in the neuraminidase-inducible CE mobility change.
Since the results in Figs. 6 and 7 indicated only a negative
effect of the N-linked termini, this enhancing effect on HA
binding appeared to be due to some aspect of the N-glycan
core. A more marked loss of affinity was observed after
N-deglycosylation of a CD44Rg glycan variant having only
N-linked and no O-linked oligosaccharides (derived from
ldl-D cells supplemented with Gal alone) (Fig. 7 F, Table
I). This finding suggests that O-glycosylation can partially
compensate for the lack of N-glycosylation, providing a
third glycosylation effect on the intrinsic HA affinity of
CD44. To further address these N-glycan–dependent ef-
fects, CD44Rg synthesized by wt CHO cells and ldl-D cells
Figure 6. Effect of glycosyla-
tion on the intrinsic CD44Rg
affinity for HA. Affinity cap-
illary electrophoresis in the
presence of the indicated con-
centrations of HA60 of (A)
wt CHO–derived CD44Rg, (B)
BSA, or (C–F) ldl-D–derived
CD44Rg synthesized in the
presence of (C) no saccharide
addition, (D) Gal only, (E)
GalNAc only, or (F) Gal 1
GalNAc. The narrow peak
due to MO, a neutral marker
included as an internal con-
trol, is labeled. The broader
unlabeled peak corresponds
to CD44Rg. The inverted
peak at the migration time
for HA60 is due to the ab-
sence of HA60 in the sample.
Mobility values for CD44Rg
and HA60 were calculated
from migration times relative
to MO. The mobility of
CD44Rg in the presence of
ligand is reported as a rela-
tive mobility (RM), where RM
is 0.0 at the mobility of the
uncomplexed CD44Rg and
RM is 1.0 at the mobility of
HA60. The migration times
corresponding to RM of 0.0
and 0.4, indicated in each
panel for the top electro-
phoretogram, were calculated
using the mobility of CD44Rg
from the CE runs at 0 mM HA60 and the migration times for MO and HA60 from the same electrophoretogram. The relative mobilities
of CD44Rg from A–F are plotted in G. Displayed curves were fit to the equation RM 5 RM (max) * [HA60]/(Kd * [HA60]) where RM is
the relative mobility, RM (max) is the maximum relative mobility (mobility of CD44Rg at saturating concentrations of HA60), Kd is the
dissociation constant, and [HA60] is the concentration of HA 60-mer. The determined values were RM (max), 0.54 and Kd, 5 and 40 mM.The Journal of Cell Biology, Volume 140, 1998 440
under each of the glycosylation conditions were analyzed
by ACE after PNGase-F or mock digestion (Fig. 8 A, Ta-
ble I). The enhancing effect of N-glycans on CD44Rg af-
finity for HA was apparent in that the HA-binding ability
of each CD44Rg glycovariant was reduced after N-glycan
removal. The decrease in affinity was more pronounced for
glycovariants lacking terminal sialic acid (ldl-D GalNAc and
ldl-D no addition) because the enhancing effect of N-glyco-
sylation was not partially offset by the inhibitory effect of
sialic acid. In addition, the fully deglycosylated CD44Rg
(PNGase-F-treated ldl-D Gal and ldl-D no addition) dis-
played poorer HA affinity than CD44Rg, which retained
truncated (ldl-D GalNAc) or intact (ldl-D Gal/GalNAc
and wt CHO) O-linked glycan structures, confirming that
the reduction in affinity after N-deglycosylation was mod-
erated by the presence of O-linked oligosaccharides. Thus,
while the O-glycans appear to have no effect on affinity in
the presence of N-linked glycans (Figs. 6; 7, E and F; and 8
A; Table I), the presence of O-glycosylation enhances af-
finity when N-glycosylation is absent (Figs. 7 and 8 A, Ta-
ble I). Taken together, these experiments reveal an en-
hancing effect on HA binding of some aspect of the CD44
N-glycan core structure, loss of which can be partially com-
pensated for by O-glycans, and an inhibitory effect of the
terminal sialic acid of N-linked oligosaccharides.
A Single N-linked GlcNAc Residue Is Sufficient to 
Promote CD44–HA Binding
To determine the minimal CD44 N-linked oligosaccharide
structure required to promote high-affinity binding of HA,
we used a combination of metabolic inhibition of N-linked
glycan synthesis by dMM/KIF, which blocks N-linked glyco-
sylation processing at a high-mannose structure (Kaushal
and Elbein, 1994; Fig. 1 C), and hydrolysis by the endogly-
cosidase Endo H, which cleaves high-mannose oligosaccha-
rides, leaving a single GlcNAc attached to the asparagine
residue (Tai et al., 1975; Fig. 1 C). Endo H cleavage of high-
mannose oligosaccharides from CD44Rg derived from wild-
type CHO cells or ldl-D cells (without monosaccharide
supplementation) cultured in the presence of dMM/KIF
generated CD44Rg glycan variants that displayed high af-
finity for HA (Fig. 8 B, Table I). In comparison, PNGase-F
treatment of CHO cell–derived and ldl-D cell–derived
CD44Rg resulted in intermediate and low HA affinity, re-
spectively (Fig. 8 B, Table I). Successful modification of
the oligosaccharide structures by synthetic blockade or glyco-
sidase digestion was confirmed by changes in CE mobility
of the CD44Rg glycan variants (data not shown). These
observations indicate that a single N-linked GlcNAc resi-
due is sufficient to provide the enhancing effect on CD44
Figure 7. Effects of glycosi-
dase digestion on the intrin-
sic CD44Rg affinity for HA.
Glycosidase-digested CD44Rg
glycovariants were analyzed
for HA affinity by ACE at
24  mM HA60. The ACE elec-
trophoretograms for ldl-D
(Gal  1 GalNAc) CD44Rg
treated with (A) mock, (B)
PNGase-F, (C) NANase-I
(N1), and (D) NANase-I 1
GALase-III glycosidase di-
gestions are shown. ACE
mobility shifts induced by
24 mM HA60 for CD44Rg
glycovariants synthesized by ldl-D in the presence of (E) Gal 1 GalNAc and (F) Gal-only medium supplementation are shown. Specific-
ities of glycosidases are: NANase-I (N1) and -II (N2), a2-3 and a2-3,6-linked sialic acid, respectively; GALase-I (G1) and -III (G3), b1-
3,4,6 and b1-4 galactose, respectively; HEXase-II; (H2) bGlcNAc or bGalNAc. Relative mobilities (RM) of 0.19 (Mock), 0.36 (N1),
and 0.17 (PNGase-F) from E correspond to dissociation constants (Kd) of 44, 12, and 52 mM, respectively. Similar results were obtained
from two other experiments.Skelton et al. Glycosylation-mediated Effects on CD44-Hyaluronan Binding 441
affinity for HA attributed to core N-linked oligosaccharide
structures (Figs. 7 and 8 A). 
Hybrid Structures Provide an Intermediate Level of 
Inhibition of Intrinsic CD44 Affinity for HA Compared 
with High-mannose and Complex-Type
N-linked Oligosaccharides
In experiments that addressed the ability of whole cells to
bind soluble HA, cells bearing hybrid oligosaccharide struc-
tures were found to display HA avidity that was intermediate
compared with the high avidity of high mannose–bearing
cells and the low avidity of cells synthesizing complex-type
oligosaccharides (Fig. 3). To determine if these effects are
caused by changes in the intrinsic ability of CD44 to bind HA,
we examined the HA affinity of CD44Rg glycovariants
bearing hybrid and high mannose–only N-linked structures
by ACE. Similar to whole cells, CD44Rg containing hybrid
structures bearing a single sialylated oligosaccharide branch
displayed intermediate HA affinity (Fig. 8 C) compared
with the high affinity of counterparts containing only high
mannose and the lower affinity of CD44Rg containing com-
plex-type oligosaccharides with multiple sialylated branches
(Fig. 1 C). 
Discussion
To identify CD44-associated oligosaccharides that are
functionally relevant to CD44–HA interaction, we have
taken advantage of a combination of selective synthetic
blockade provided by ldl-D cells or metabolic mannosi-
dase inhibitors and recombinant glycosidase digestion to
generate glycoforms of CD44 with precisely defined changes
in oligosaccharide structure for affinity analysis by ACE.
This approach has helped identify four distinct oligosac-
charide structure– and linkage-dependent effects of glyco-
sylation on the ability of cell surface and soluble CD44 to
bind HA. They are (a) a reduction in binding ability by
a2,3sialylation of N-linked oligosaccharides, (b) an in-
crease in binding ability by the asparagine-linked GlcNAc
of the invariant N-linked glycan core structure, (c) an in-
crease in binding ability by O-linked glycosylation of N-degly-
cosylated CD44; and (d) a GalNAc-dependent increase in
HA binding by cell surface CD44. The first three effects
were demonstrated using soluble CD44, indicating alter-
ations in the affinity for HA of the CD44 glycoprotein it-
self, in the absence of cellular constraints, with a Kd ranging
from 5 to .150 mM. The fourth effect augmented CD44-
mediated cell binding of HA without changing the affinity
for HA of the soluble CD44 glycoprotein itself. 
Three Types of Glycosylation Changes That Affect 
CD44 Affinity for HA Are Uncovered by ACE
A summary of the Kd values obtained from several ACE
experiments on each CD44Rg glycovariant is shown in Ta-
ble I. The differences in the intrinsic affinity for HA among
the purified CD44Rg glycovariants can be explained by
Table I. Micromolar Dissociation Constants (Kd) for HA of each CD44Rg Glycovariant
Cell line Media addition N-Glycans O-Glycans Kd 6 SD Enzyme treatment N-Glycans O-Glycans Kd
mM mM
CHO Intact Intact 51 6 19 PNG-F Absent Intact 76
ldl-D Gal/GalNAc Intact Intact 45 6 4 PNG-F Absent Intact 62
ldl-D Gal Intact Absent 47 6 13 PNG-F Absent Absent .150
ldl-D No Addition Truncated Absent 8 6 1 PNG-F Absent Absent .150
ldl-D GalNAc Truncated Truncated 8 6 2 PNG-F Absent Truncated 112
CHO dMM/KIF High Intact 12 Endo H GlcNAc Intact 6
mannose
ldl-D dMM/KIF High Absent 10 Endo H GlcNAc Absent 5
mannose
CHO Swainsonine Hybrid Intact 22
CHO NANase Asialo- Present 12
CHO NANase/ Asialo- Present 12
GALase Agalacto-
CHO NANase/ Trimmed Present 9
GALase/
HEXase
ldl-D Gal/GalNAc NANase Asialo- Present 13
ldl-D Gal/GalNAc NANase/ Trimmed Present 13
GALase/
HEXase
ldl-D Gal NANase Asialo- Absent 18
ldl-D Gal NANase Asialo- Absent 14
GALase Agalacto-
ldl-D Gal NANase/ Trimmed Absent 14
GALase/
HEXase
Summary table of the micromolar dissociation constant (Kd) for each CD44Rg glycovariant obtained from the mean of two to seven ACE experiments. The standard deviation
of the mean Kd is shown for values obtained from four or more experiments. PNG-F, peptide N-glycanase F; NANase, a-neuraminidase; GALase, b-galactosidase; HEXase,
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three glycosylation-dependent effects. First, the higher af-
finity of CD44Rg glycovariants having truncated, high-
mannose, residual single GlcNAc, or enzymatically desia-
lylated N-glycans compared with CD44Rg molecules having
intact N-glycans is explained by the absence of inhibitory
terminal sialic acid residues on N-linked oligosaccharides.
By extension, a Kd of 22 mM for the CD44Rg glycovariant
bearing hybrid-type N-glycans is consistent with partial
sialic acid–mediated inhibition and suggests that the de-
gree of inhibition is directly related to the number of oli-
gosaccharide branches terminating in sialic acid. Second,
the higher HA affinity of CD44Rg glycoproteins with an
N-glycan present (intact, truncated, high-mannose, GlcNAc,
exoglycosidase-treated, or hybrid) compared with CD44Rg
molecules lacking an N-glycan (PNGase-F treated) is ex-
plained by the enhancing effect of the asparagine-linked
GlcNAc. Finally, the higher HA affinity of N-deglycosy-
lated CD44Rg glycovariants containing O-glycans (intact
or truncated) compared with completely deglycosylated
CD44Rg proteins (O-glycans absent) is attributed to an
enhancing effect of the O-glycans on N-deglycosylated CD44.
Calculation of the standard deviation for the Kd values
obtained from several independent ACE experiments us-
ing CD44Rg derived from CHO or ldl-D cells under each
of the tested glycosylation conditions illustrates the degree
of variability in CD44Rg-HA affinity measured by this as-
say (Table I). Significantly higher interexperimental varia-
tion in receptor–ligand affinity was associated with CD44Rg
produced in CHO cell or ldl-D cells/Gal–only supplemen-
tation than with the other CD44Rg glycovariants. The ob-
served variation was found to be caused by differences in
the degree of sialylation of CD44Rg derived from one tissue
culture batch to the next and was demonstrated by batch-
to-batch differences in neuraminidase-inducible changes
in CD44Rg CE mobility (data not shown). After neura-
minidase-mediated removal of sialic acid, CD44Rg mole-
cules derived from different production batches were found
to display the same CE mobility. Differences in CHO- and
ldl-D/Gal cell–derived CD44Rg sialylation may be ex-
plained by variable release of soluble neuraminidase from
cells cultured under suboptimal nutrient conditions (Warner
et al., 1993; Ferrari et al., 1994). Neuraminidase released
into the culture medium after CHO cell lysis can desialy-
late recombinant soluble glycoproteins (Warner et al., 1993).
A similar mechanism may underlie the observed variabil-
ity in CD44Rg sialylation and is supported by the much
Figure 8. Characterization of three distinct effects of CD44 gly-
cosylation on its intrinsic affinity for HA by ACE analysis of
CD44Rg glycovariants. CD44Rg with defined oligosaccharide modi-
fications were analyzed for HA affinity by ACE at 24 mM HA60.
Error bars are 1 SD. (A) CD44Rg glycan variants were synthe-
sized by ldl-D cells cultured in the presence of the indicated sac-
charide additions were treated with (PNGase-F) or without
(Mock) enzymatic removal of N-linked oligosaccharides. (B)
CD44Rg glycan variants generated in CHO cells bearing intact
O-linked and complex-type (CHO) or high-mannose N-linked
oligosaccharides (CHO dMM/KIF), or in ldl-D cells, grown with-
out saccharide supplementation, lacking O-linked and bearing
truncated complex-type (ldl-D No Add) or high-mannose
N-linked oligosaccharides (ldl-D dMM/KIF) were treated with
the indicated glycosidases before affinity analysis. Structures expected for peptide N-glycanase-F (PNGase-F) and Endo H digestions
are shown in Fig. 1 C. Specificity for the neuraminidase (N3) is a2-3,6,8 sialic acid. (C) CD44Rg glycan variants were generated in CHO
cells bearing intact O-linked and complex-type (Untreated), high-mannose (dMM/KIF), or hybrid-type (Swainsonine) N-linked oli-
gosaccharides. The same results were obtained in at least one other experiment for each panel.Skelton et al. Glycosylation-mediated Effects on CD44-Hyaluronan Binding 443
tighter Kd values associated with nonsialylated CD44Rg
glycovariants (ldl-D no addition and ldl-D GalNAc). In-
terestingly, the degree of variation in HA affinity of
CD44Rg derived from ldl-D cells supplemented by Gal
and GalNAc was not as high as that of CD44Rg synthe-
sized under the other two sialylation-competent synthetic
conditions (CHO and ldl-D Gal only). A possible explana-
tion for this difference is that the ldl-D Gal/GalNAc cells
(as well as ldl-D no addition and ldl-D GalNAc cells) were
consistently found to be more effectively growth arrested
by serum starvation than wt CHO cells or ldl-D Gal–only
cells. It therefore appears plausible that during the long se-
rum-free culture periods required for generation of ade-
quate quantities of CD44Rg, wt CHO and ldl-D Gal–only
cells may grow beyond the ability of the media to support
viability, resulting in significant cell lysis and release of a
soluble neuraminidase into the culture media.
The Kd values obtained (Table I) allowed us to estimate
the magnitude of each of the glycosylation-dependent ef-
fects on CD44Rg affinity for HA. Thus, we observed a
four- to eightfold inhibition of HA binding attributable to
N-linked sialic acid. However, considering the possible
partial loss of CD44Rg-associated sialic acid in the cell cul-
ture medium in some of these experiments, the eightfold
decrease in HA affinity displayed by the more highly sialy-
lated CD44Rg molecules is more likely to reflect the ac-
tual degree of sialic acid–mediated inhibition of HA bind-
ing by endogenous CD44 in CHO cells. Asparagine-linked
GlcNAc provides a greater than 30-fold enhancement of
HA affinity demonstrated by the Kd values of fully degly-
cosylated CD44Rg (.150 mM; ldl-D no addition PNGase-
F) and CD44Rg containing N-linked GlcNAc as its only
glycan (5 mM; ldl-D no addition dMM/KIF Endo H). The
presence of intact O-glycans on N-deglycosylated CD44Rg
provides about a 2.5-fold affinity enhancement (Kd of 62 mM
versus .150 mM).
Essential to the determination of the effect of different
glycans on CD44 function was the use of affinity capillary
electrophoresis. To our knowledge, this study represents
the first described application of ACE to the analysis of a
physiological cell surface receptor–ligand interaction. ACE
revealed that the dissociation rate of HA from CD44Rg in
free solution (,5 s in ACE experiments, data not shown)
was much higher than the dissociation rate of soluble HA
from the intact cell (.30 min in FACS® experiments). The
greater HA avidity in the intact cell is presumably due to
multivalent interactions between the high–molecular weight
FITC-HA and multiple cell surface CD44 molecules. This
interpretation is supported by observations that glycan
modifications which alter the intrinsic CD44 affinity for
HA yield a corresponding change in whole cell avidity,
which is a function of intrinsic receptor–ligand affinity and
valency. In light of the observation that GalNAc supple-
mentation of ldl-D cell culture medium augments cell sur-
face but not soluble CD44–HA binding, it appears likely
that glycosylation can affect cell surface CD44-mediated
cell adhesion to HA by mechanisms other than intrinsic
receptor–ligand affinity. Such additional cell context-depen-
dent mechanism(s) may allow CD44 to form higher va-
lency interactions with HA molecules or may alter CD44
affinity for HA by promoting interactions between CD44
and other receptors on the cell surface.
ACE Analysis of CD44 Glycovariant Ability to Bind HA 
Provides Explanations for the Seemingly Contradictory 
Results of Earlier Studies
The multiple effects of glycosylation on CD44 affinity
characterized in this study offer a means to reconcile the
apparently conflicting results of previous reports. The in-
hibition of affinity by the terminal sialic acid of N-linked
oligosaccharides is consistent with the studies by Katoh et al.
(1995), who found activation of HA binding by neuramini-
dase treatment of some cell lines, a subset of splenic B
cells, and CD44-coated beads. In addition, this mechanism
of inhibition is consistent with studies that reported an
augmentation of HA binding by some cell lines treated
with dMM (Lesley et al., 1995; Bartolazzi et al., 1996; Slee-
man et al., 1996) or dMM/KIF (this study). The inability of
neuraminidase or dMM treatment to enhance HA binding
by some CD44-expressing cell lines may be explained by
the absence of sialic acid on the N-linked oligosaccharides
of CD44 in these cells. In one such example, an SDS-
PAGE mobility shift for CD44 was observed after neu-
raminidase treatment (Lesley et al., 1995) but may be ex-
plained by a loss of O-linked sialic acid, which would have
no effect on intrinsic HA affinity. Alternatively, CD44 ex-
pressed in non–HA-binding cell lines may be maintained
in an inactive state regardless of its N-linked glycosylation
pattern by additional cell context-based mechanisms, one
of which may be provided by glycosaminoglycans (GAG)
(Lesley et al., 1995). Our results are also consistent with
the high level of CD44-mediated HA binding by the Lec 8
cell line (Katoh et al., 1995), a CHO mutant with a nonre-
versible defect in UDP-galactose transport, which is the
functional equivalent of ldl-D cells supplemented by Gal-
NAc alone.
The results of the present study provide an explanation
for the apparent discrepancy between the biosynthetic
studies of Lokeshwar and Bourguignon (1991), where an
enchancing effect on HA binding by CD44 O-glycosyla-
tion was reported, and those of Lesley et al. (1995), which
found that inhibiting CD44 O-glycan extension by benzyl-
a-GalNAc had no effect on HA binding. The biosynthetic
experiments that detected a positive role for O-glycosyla-
tion were performed in the presence of tunicamycin, an in-
hibitor of N-glycosylation. As a result, the nonglycosylated
ER CD44 precursor did not bind HA but acquired HA
binding ability upon O-glycosylation in the Golgi (Lokesh-
war and Bourguignon, 1991). In the absence of tunicamy-
cin, the N-glycosylated ER precursor was able to bind HA.
In contrast, the lack of an effect of metabolic inhibition of
CD44 O-glycosylation (confirmed by SDS-PAGE mobility
change) in a number of cell lines reported by Lesley et al.
(1995) was observed under conditions where CD44 was
N-glycosylated. Taken together, the observations of these
two studies are consistent with the enhancing effect of any
N-glycan core and the enhancing effect of O-glycans on
CD44 molecules lacking N-glycans described in the present
study. These results can therefore be explained by glycosy-
lation-dependent changes in the intrinsic affinity of the
CD44 molecule for ligand without invoking the involve-
ment of other molecules or cell type–specific differences.
Reports of inhibition of HA binding by O-glycosylation of
CD44 itself appear to be limited to examples of variableThe Journal of Cell Biology, Volume 140, 1998 444
exon usage that provides new attachment sites for inhibi-
tory O-glycans (Bennett et al., 1995). The report that
CD44-mediated HA binding could be augmented by para-
nitrophenol-xyloside, an inhibitor of GAG synthesis, sug-
gests an inhibitory role for these glycoconjugates (Lesley
et al., 1995). However, GAGs were not found on the
CD44 molecule in that study, suggesting that the observed
inhibitory effect may be due to GAGs associated with
other cell surface structures. Taken together, these reports
are consistent with our finding that O-glycosylation of the
standard form of CD44, CD44H, has no effect on the in-
trinsic affinity for HA in the (presumably) physiological
situation of N-glycan–modified CD44. 
Our finding that a single N-linked GlcNAc is sufficient
to induce a 30-fold enhancement in CD44 affinity for HA
offers a potential explanation for the apparent discrepancy
between a loss of CD44–HA binding (Bartolazzi et al.,
1996) and a 10-fold increase in CD44–HA binding (Katoh
et al., 1995) after enzymatic N-deglycosylation. In the first
study, PNGase-F was used as the deglycosylating enzyme,
while the second study was performed using a combina-
tion of PNGase-F and Endo-F, an enzyme that cleaves be-
tween the first and second GlcNAc, leaving a single N-linked
GlcNAc. Studies using tunicamycin, on the other hand, are
more difficult to interpret, in part because of the broad ef-
fects of blocking N-glycosylation of all cellular glycopro-
teins. Activation or inhibition of CD44–HA binding can
be obtained depending on the duration of tunicamycin
treatment (Sleeman et al., 1996), and even after prolonged
treatment, a significant fraction of CD44 molecules remain
N-glycosylated (Katoh et al., 1995; Sleeman et al., 1996).
In the extended serum-free culture conditions used in the
present study, tunicamycin was toxic to the cells.
Potential Physiological and Nonphysiological 
Glycosylation-dependent Regulation of the Ability of 
CD44 to Bind HA
Clearly, it is important to distinguish between functional
alterations associated with glycosylation changes that may
be physiologically relevant and those that may arise only
in an experimental system. Thus, the low HA affinity of the
fully deglycosylated CD44Rg and the increased affinity con-
tributed by the presence of O-linked glycosylation in the
absence of N-linked glycans are unlikely to reflect physio-
logical phenomena. In contrast, effects observed after more
modest changes in specific saccharide residues of the ter-
minal oligosaccharide modifications are more likely to ap-
proximate physiological regulatory mechanisms. The cell
could therefore potentially regulate CD44 function by mod-
ulating specific glycosyltransferase activity that would re-
sult in synthesis of CD44 molecules with altered branching
or sialylation of their N-linked oligosaccharides. However,
it is also possible that the effects on CD44 function of the
first GlcNAc of N-linked glycans and of O-linked GalNAc
may have biological significance in a site-specific fashion. In
other words, modulation of the efficiency of the N-oli-
gosaccharide transfer to specific CD44 N-glycan attachment
sites or regulation of one of the newly identified GalNAc-
transferases that initiate site-specific O-linked glycosyla-
tion (Clausen, H., and E. Bennett. 1997. Glycoconj. J. 14:
S8; Nehrke, K., F.K. Hagen, K.G. Ten Hagen, J. Zara, and
T.A. Tabak. 1997. Glycoconj. J. 14:S8) are two possible
mechanisms by which the cell could control CD44 function.
The finding that a single GlcNAc residue is sufficient to
provide the enhancing effect of N-glycans on ligand bind-
ing, observed for CD44 in this study, was also previously
observed for the cell adhesion molecule CD2 (Wyss et al.,
1995). A single Asn-linked GlcNAc stabilizes human CD2
by counterbalancing an unfavorable cluster of five positive
charges via hydrogen bonds and van der Waals contacts to
the polypeptide. Complete deglycosylation results in un-
folding of the CD2 protein and loss of binding to its natu-
ral ligand CD58 at a site distant from the glycosylation-
charge cluster interaction. Interestingly, in contrast to human
CD2, rat CD2 lacks an N-linked glycosylation site but main-
tains a stable protein conformation by replacing one of
the cluster’s positively charged lysines with a negatively
charged glutamic acid. It thus seems that the structural sta-
bilizing role of N-glycosylation of CD2 does not involve
specific structures but rather is a product of the coevolu-
tion of glycosylation and amino acid changes within the
physiochemical restraints for protein folding and stability.
In the case of CD44, N-linked oligosaccharide structures
may have evolved a specific regulatory function, while the
coevolving amino acid changes may have developed the
required interactions with the existing glycan core. In this
way, CD44-associated N-linked glycans may have ac-
quired a nonspecific protein stabilizing role, similar to the
N-linked oligosaccharide of CD2. Our structure–function
studies of the N-linked oligosaccharides on CD44 have
identified candidates for both a nonspecific protein stabi-
lizing role, shown by the positive effect of a single N-linked
GlcNAc, and a specific regulatory role, shown by the neg-
ative effect of terminal sialylation. 
Terminal a2,3-sialylation of complex-type oligosaccharides
provides a plausible mechanism for the cellular regulation
of HA binding by CD44. Since sialic acid is the terminal
modification on N-linked oligosaccharides, alteration of the
expression/function of the relevant sialyltransferase can
provide a means for the cell to regulate CD44-mediated
adhesiveness. Recent evidence indicates that N-linked oli-
gosaccharide sialylation regulates the ability of at least
three I-type lectins, CD22, CD33, and sialoadhesin, to in-
teract with their ligands (Braesch-Andersen et al., 1994;
Freeman et al., 1995). CD22, a B lymphocyte–specific re-
ceptor thought to be involved in B cell activation, loses its
ability to bind ligands upon sialylation by a b-galactoside
a2,6 sialyltransferase which is upregulated in activated B
cells. Linkage-specific sialylation of CD22 may therefore
provide a regulatory mechanism for its function (Sgroi and
Stamenkovic, 1994). Our present data suggest an analo-
gous mechanism as a candidate physiological regulator of
CD44-mediated HA binding, where cell activation by vari-
ous stimuli may alter the relevant a2,3-sialyltransferase ac-
tivity, resulting in altered sialylation of CD44 and HA af-
finity. 
The relatively high HA affinity of CD44Rg bearing hy-
brid-type oligosaccharides (Fig. 8 C) and the relatively high
HA avidity of cells cultured in the presence of swainson-
sine (Fig. 3 B) suggest that regulation of oligosaccharide
branching offers an alternative mechanism for determin-
ing the amount of CD44 sialylation. Thus, regulation of the
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oligosaccharide intermediates to determine the final branch-
ing pattern of N-linked oligosaccharides may be impli-
cated in controlling CD44 function. For example, increased
activity of GlcNAc–transferase III or of an earlier acting
b1-4galactosyltransferase would be expected to generate a
greater number of hybrid-type oligosaccharides and pro-
duce CD44 molecules with relatively high affinity for HA.
On the other hand, increased GlcNAc–transferase V activ-
ity would be expected to generate an increased number of
complex-type branches and/or extended sialylated branches
and produce a CD44 molecule with lower HA affinity. These
possibilities are particularly interesting in view of the asso-
ciation of changes in GlcNAc-transferase III (Yoshimura
et al., 1995) and GlcNAc–transferase V (Dennis and La-
ferte, 1989; Fernandes et al., 1991) activity with highly
metastatic tumors and the implication of CD44 in the met-
astatic process. 
How might the enhancing effect of GalNAc on cell sur-
face CD44 binding of HA be explained? It is possible that
the GalNAc-dependent activation of HA binding by
whole cells, which is mediated by CD44 but not attribut-
able to altered intrinsic CD44 affinity for HA, is related to
a cell context–associated regulatory mechanism. Although
GalNAc can occasionally be found on complex-type N-linked
oligosaccharides, the observed GalNAc-associated aug-
mentation of HA binding was unaltered by culturing the
cells in the presence of dMM/KIF (Fig. 3 A and data not
shown). Thus, activation of HA binding by GalNAc appears
to be unrelated to the N-glycan structures. Furthermore,
we were unable to show a GalNAc-related difference in
CD44 cell surface distribution or in CD44 oligomerization.
Because the absence of GalNAc prevents O-linked glyco-
sylation on all cell surface glycoproteins, it would appear
likely that the observed effect is nonphysiological. How-
ever, we cannot exclude the possibility that the O-linked
oligosaccharides on CD44 may regulate its interaction
with functionally relevant accessory molecules and thereby
promote a physiological regulatory mechanism that would
not be apparent in ACE analysis. Perhaps more likely, the
loss of all surface O-linked glycosylation can be expected
to have profound effects on the membrane mobility and
interactions of surface glycoproteins (Wier and Edidin,
1988) that could account for the observed differences in
cellular avidity. 
Finally, glycosylation is probably not the only regulatory
mechanism of CD44–HA interaction. The heterogeneity
of HA binding among cells in a CHO cell population ob-
served by FACS® analysis does not appear to be due to
glycosylation-dependent variation in intrinsic CD44 affin-
ity for HA since CD44Rg molecules synthesized by the
same cell population display uniform affinity for HA as
assessed by ACE. One possible explanation for this dis-
crepancy is that CD44-mediated HA binding by the cell is
regulated in part by a mechanism that is unrelated to glyc-
osylation and that at any given time may be active in only
a fraction of cells. 
In summary, we have developed a novel approach for
analyzing the effects of glycosylation on adhesion mole-
cule function that may be generally applicable. Our results
show that glycosylation can regulate the HA-binding abil-
ity of CD44 in at least four different ways, which may ex-
plain some of the apparently contradictory observations
on the functional role of CD44 glycosylation. Of the four
observed glycosylation-dependent effects, a2,3 sialylation
of N-linked glycans on the CD44H polypeptide and possi-
bly O-linked structures provide candidate participants in
the physiological regulation of CD44–HA interaction.
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